Provider Comfort with Prescribing HIV Pre-Exposure Prophylaxis to Adolescents.

{"article_title":"Provider Comfort with Prescribing HIV Pre-Exposure Prophylaxis to Adolescents.","author":"na","journal_title":"AIDS patient care and STDs","issn":"1557-7449 ; Electronic","isbn":"","publication_date":"20211001","volume":"35","issue":"10","first_page":"411","page_count":"7","accession_number":"34623888","doi":"10.1089\/apc.2021.0045","publisher":"Mary Ann Liebert, Inc","doctype":"Journal Article; Research Support","subjects":"Medicine ","interest_area":["Infectious Disease & Vaccines"," Internal\/Family Medicine"],"abstract":"In the United States, Black and Latinx youth remain disproportionately affected by HIV. Oral antiretroviral pre-exposure prophylaxis (PrEP) is a proven effective HIV prevention strategy. PrEP is approved for use in people younger than the age of 18 years, but little is known about provider comfort and preparedness with prescribing it to adolescents. In this study, physicians provide their perspectives on the facilitators and barriers to PrEP access among adolescents. Focus groups ( <i>n<\/i> = 23) were conducted with pediatric and family practitioners practicing in an urban community hospital setting to assess PrEP awareness and receptivity to use among adolescents. Most providers were unfamiliar with clinical guidelines for PrEP use, especially in determining adolescent candidates for PrEP use, including appropriate dosing regimen and follow-up procedures. Overall, providers had low intent on prescribing PrEP, citing concerns about consent, medication adherence, and appropriateness of primary care providers in prescribing and managing adolescent PrEP use. Strategies that will address provider education and comfort in prescribing PrEP to adolescents are required to increase PrEP access and uptake among communities disproportionally affected by HIV.","url":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&db=mdl&AN=34623888&authtype=shib&custid=ns346513"}